Krystal Biotech, Inc. (KRYS) Tops Q2 EPS by 7c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results
August 4, 2025 7:00 AM EDT$96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023
VYJUVEK approved in Japan for the treatment of DEB patients from birth
Strong balance sheet, ending the quarter with $820.8 million in cash and investments
PITTSBURGH, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS) today reported financial results for the second quarter ending June 30, 2025 and provided a business update.
With the approval of VYJUVEK in Europe and Japan, we are on the cusp... More
